title: Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong.
abstract: A recently published paper that assessed the comparative cost-effectiveness of the 2 pneumococcal conjugate vaccines (PCVs) in Malaysia and Hong Kong reported that the 13-valent PCV vaccine (PCV13) is a better choice compared to the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV or PCV10) from both a payer and societal perspective as well as under various scenarios. However, the analysis relied on a large number of assumptions that were either erroneous or did not take into account the most recent body of evidence available. A rigorous evaluation of the underlying assumptions is necessary to present a fair and balanced analysis for decision-making.
authors.affiliation: a GSK Vaccines , Singapore , Singapore.
authors.forename: Lijoy
authors.initials: L
authors.lastname: Varghese
authors.affiliation: a GSK Vaccines , Singapore , Singapore.
authors.forename: Bruce
authors.initials: B
authors.lastname: Mungall
authors.affiliation: a GSK Vaccines , Singapore , Singapore.
authors.forename: Xu-Hao
authors.initials: XH
authors.lastname: Zhang
authors.affiliation: b GSK Vaccines , Wavre , Belgium.
authors.forename: Bernard
authors.initials: B
authors.lastname: Hoet
mesh_terms: D003362:Cost-Benefit Analysis; D006723:Hong Kong; D006801:Humans; D007223:Infant; D008296:Malaysia; D011008:Pneumococcal Infections / Q000191:economics / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology*
chemical_list: C586648:10-valent pneumococcal conjugate vaccine; C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines
keywords: 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV); 13-valent pneumococcal conjugate vaccine (PCV13); cross-protection; herd effect; nasopharyngeal carriage; non-typeable Haemophilus influenzae (NTHi); pneumococcal conjugate vaccine (PCV)